BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Hancock MA" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity | Pierre Bikorimana J; Caveney NA; El-Hachem N; Mandl GA; Capobianco JA; Stanga D; Abusarah J; Hancock MA; Farah R; Gonçalves MP; Falzarano D; Liao M; Hamonic G; Liu Q; Beaudoin S; Talbot S; Rafei M; | 41054531 CNSR |
| 2 | Carbohydrate esterase family 16 contains fungal hemicellulose acetyl esterases (HAEs) with varying specificity | Venegas FA; Koutaniemi S; Langeveld SMJ; Bellemare A; Chong SL; Dilokpimol A; Lowden MJ; Hilden KS; Leyva-Illades JF; Mäkelä MR; My Pham TT; Peng M; Hancock MA; Zheng Y; Tsang A; Tenkanen M; Powlowski J; de Vries RP; | 35405333 CSFG |
| Title: | A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity | ||||
| Authors: | Pierre Bikorimana J, Caveney NA, El-Hachem N, Mandl GA, Capobianco JA, Stanga D, Abusarah J, Hancock MA, Farah R, Gonçalves MP, Falzarano D, Liao M, Hamonic G, Liu Q, Beaudoin S, Talbot S, Rafei M | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/41054531/ | ||||
| DOI: | 10.1016/j.isci.2025.113314 | ||||
| Publication: | iScience | ||||
| Keywords: | Biological sciences; Immune response; Immunology; Natural sciences; | ||||
| PMID: | 41054531 | Category: | Date Added: | 2025-10-07 | |
| Dept Affiliation: |
CNSR
1 Department of Microbiology, Infectious Diseases, and Immunology, Université de Montréal, Montreal, QC H3T 1J4, Canada. 2 Centre for Blood Research, University of British Columbia, Vancouver, BC V6T 1Z3, Canada. 3 Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada. 4 Sainte-Justine Research Centre, Montreal, QC H3T 1C5, Canada. 5 Department of Chemistry and Biochemistry and Centre for NanoScience Research, Concordia University, Montreal, QC H3T 1J4, Canada. 6 Research and Development Branch, Defence Therapeutics Inc., Montreal, QC H4S 1Z9, Canada. 7 Department of Pharmacology and Physiology, Université de Montréal, Montreal, QC H3T 1J4, Canada. 8 SPR-MS Facility, Department of Pharmacology and Therapeutics, McGill University, Montreal, QC H3G 1Y6, Canada. 9 Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, SK S7N 5E3, Canada. 10 Department of Biomedical & Molecular Sciences, Queen's University, Kingston, ON K7L 3J8, Canada. 11 Molecular Biology Program, Université de Montréal, Montreal, QC H3T 1J4, Canada. |
||||
Description: |
Despite the recent control of COVID-19, the devastating effects caused by the 3-year pandemic highlight the importance of developing effective vaccines to rapidly address future outbreaks. The present study describes a novel Spike (Sp) protein-based vaccine formulation using the Accum platform. Although Sp-Accum bioconjugation does not alter the overall protein structure, it triggers a substantial antibody titer: i) exhibiting higher specificity toward the S1 domain of Sp, ii) neutralizing Sp-ACE2 interactions, and iii) cross-reacting with various Sp variants. Besides validating the vaccine immunogenicity in rabbits, its administration in a "gold-standard" SARS-CoV-2 hamster model was shown to be safe while accelerating viral clearance without eliciting signs of pathological inflammation in the lungs of infected animals. Altogether, this proof-of-concept study not only demonstrates once again the versatility of the Accum technology in vaccine engineering, but it provides an enabling technology for the rapid development of value-added, protein-based vaccines for future pandemics. |
